|
|
|
|
|
|
|
11.12.25 - 15:48
|
New Lilly Shot Reduces Body Weight by 23% in Study (Bloomberg)
|
|
|
A next-generation obesity shot from Eli Lilly helped patients lose nearly a quarter of their body weight, potentially making the experimental drug the most potent weight-loss medicine yet. Madison Muller reports on Bloomberg Television. (Source: Bloomberg)...
|
|
|
|
|
|
|
11.12.25 - 15:21
|
Lilly′s Next-Gen Obesity Shot Shows Best-In-Class Weight Loss In Study (ZeroHedge)
|
|
|
Lilly's Next-Gen Obesity Shot Shows Best-In-Class Weight Loss In Study
Shares of Eli Lilly are higher in premarket trading after the company unveiled blowout topline results for its next-generation obesity drug retatrutide, which delivered more than 23% weight loss over 68 weeks - the strongest performance yet for a late-stage obesity trial.
Adult patients in the Phase 3 TRIUMPH-4 trial testing retatrutide, a first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist, entered the study with obesity or overweight and knee osteoarthritis. Most participants had a BMI of 35 or higher.
Result highlights for both high-dose regimens (9 mg and 12 mg):
Met all primary and key secondary endpoints
Produced massive weight loss: up to 28.7% on average (71.2 lbs) at 68 weeks
Delivered major pain improvement: up to 4.5 points (75.8%) reduction on the WOMAC pain score
Improved physical function, in addition to weight and pain outcomes
"We are encouraged by the results of TRIUMP...
|
|
|
|
|
|
|
|
|
|
|
11.12.25 - 14:03
|
Crux Adds Obesity Management Medicine to its Newly Launched Employer Benefit Platform (Business Wire)
|
|
|
Employers can join the waitlist today to learn how the company is making high-demand benefits—starting with GLP-1s for obesity management—more affordable for America's workforce
MCLEAN, Va.--(BUSINESS WIRE)--Crux, the first no-fee benefits platform working directly with pharmaceutical companies and employers of all sizes to expand transparent and affordable access to transformative FDA-approved medications, today announced Eli Lilly and Company's Zepbound® will be the first medication available on its platform.
Employers will be able to contribute non-taxed dollars to lower their employees' out-of-pocket costs for branded therapies, starting with obesity management medicine. U.S.-based employers can join Crux's waitlist at getcrux.com to learn more and begin onboarding their organizations and employees. Employers will be able to launch with prescriptions shipping in early 2026.
"Despite overwhelming employee demand, less than half of employer-sponsored insurance plans cover GLP-1 medications...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
